S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
IMUX · Immunic, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$7.54
+0.16
(+2.17%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$7.54
$7.45
$7.82
52-WEEK RANGE
$7.54
$5.06
$17.43
What's happening
- IMUX is up 2.17% today, trading at $7.54. — Live quote
- Volume today (21,615) is well below its 3-month average of 273,690. (Finnhub fundamentals)
- Reports earnings on 2026-11-11 (before market open), 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.80 actual vs. $-1.22 estimated (+34.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 9
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
IMUX
+38.76%
vs S&P 500
+25.99%
1-YEAR RETURN
IMUX
-11.36%
vs S&P 500
-25.92%
6-MONTH RETURN
IMUX
-25.90%
3-MONTH RETURN
IMUX
-51.09%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.80
Est. $-1.22
BEAT +34.3%
2026-04-26 (Q1 2026)
$-1.08
Est. $-0.93
MISS -16.0%
2026-01-26 (Q4 2025)
$-0.70
Est. $-0.96
BEAT +27.1%
2025-10-26 (Q3 2025)
$-1.30
Est. $-1.71
BEAT +23.9%
Valuation Measures & Ratios
Enterprise Value4-$53.4M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book71.64
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-95.67%
Return on Assets (ROA9)-107.88%
Avg Volume (3M)273,690
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $655.6M | $333.4M | $1.75B | $92.5M | $109.6M |
| P/E | -5.50 | -3.02 | -17.08 | -0.94 | -1.09 |
| Price/Book | 5.14 | 2.20 | 166.33 | 2.73 | -20.73 |
| EV/EBITDA | -4.12 | -1.30 | -16.23 | — | — |
| ROE | -93.34% | -73.04% | -973.81% | -289.11% | 1906.66% |
| ROA | -74.82% | -58.22% | -251.18% | -159.60% | -491.37% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,075,709
Change from Prior Settlement+15.65%
% of Float—
Days to Cover (Short Ratio)4.56
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-09-18; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -11.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on IMUX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$35.3M | -$33.2M | -$26.0M | -$27.1M | -$26.8M | -$25.7M | -$22.8M | -$23.9M |
| Net income | -$34.1M | -$32.6M | -$25.6M | -$26.8M | -$25.5M | -$24.4M | -$21.4M | -$29.6M |
| EPS (diluted) | $-0.80 | $-1.08 | $-0.13 | $-2.03 | $-2.51 | $-0.24 | $-0.21 | $-0.30 |
| EPS (basic) | $-0.80 | $-1.08 | $-0.13 | $-2.03 | $-2.51 | $-0.24 | $-0.21 | $-0.30 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $159.2M | $189.7M | $24.1M | $40.7M | $61.4M | $20.5M | $40.9M | $64.8M |
| Total liabilities | $31.6M | $38.5M | $30.7M | $30.2M | $27.5M | $25.8M | $22.4M | $23.5M |
| Stockholders' equity | $127.6M | $151.2M | -$6.7M | $10.5M | $33.9M | -$5.3M | $18.4M | $41.2M |
| Total current assets | $157.8M | $188.8M | $22.9M | $39.3M | $59.8M | $19.0M | $39.3M | $63.3M |
| Total current liabilities | $31.3M | $38.4M | $30.6M | $30.1M | $27.3M | $25.6M | $22.2M | $23.4M |
| Cash & equivalents | $155.1M | $186.6M | $15.5M | $35.1M | $55.3M | $14.3M | $35.7M | $59.1M |
| Other current assets | $850.0K | $1.1M | $831.0K | $818.0K | $861.0K | $1.3M | $1.1M | $757.0K |
| Property, plant & equipment | $771.0K | $566.0K | $608.0K | $640.0K | $612.0K | $572.0K | $545.0K | $618.0K |
| Goodwill | — | — | — | — | — | — | — | — |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $12.7M | $11.0M | $10.1M | $7.9M | $7.9M | $6.0M | $7.8M | $6.0M |
| Accrued liabilities | $17.9M | $22.4M | $18.6M | $19.5M | $18.1M | $18.3M | $12.9M | $16.2M |
| Other current liabilities | $743.0K | $4.9M | $1.8M | $2.7M | $1.3M | $1.3M | $1.4M | $1.1M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $13.0K | $11.0K | $9.0K | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K |
| Retained earnings | -$675.3M | -$641.2M | -$608.6M | -$589.3M | -$563.7M | -$536.9M | -$511.4M | -$486.2M |
| Accumulated other comprehensive income (loss) | $2.8M | $3.1M | $2.6M | $2.6M | $2.5M | $3.9M | $4.2M | $3.9M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.0M | -$17.3M | -$19.3M | -$20.1M | -$24.6M | -$21.8M | -$23.0M | -$20.8M |
| Investing cash flow | -$249.0K | -$2.0K | -$11.0K | -$67.0K | -$36.0K | -$47.0K | -$3.0K | -$50.0K |
| Financing cash flow | $118.0K | $188.6M | $59.0K | $0 | $65.5M | $0 | $77.0K | $0 |
| Free cash flow | -$31.2M | -$17.3M | -$19.3M | -$20.2M | -$24.6M | -$21.8M | -$23.0M | -$20.8M |
| Capital expenditures | $249.0K | $2.0K | $11.0K | $67.0K | $36.0K | $47.0K | $3.0K | $50.0K |
| Depreciation & amortization | $34.0K | $33.0K | $42.0K | $40.0K | $43.0K | $43.0K | $35.0K | $42.0K |
| Share-based compensation | $6.8M | $4.5M | $1.3M | $3.6M | $1.9M | $2.0M | $2.0M | $1.9M |
| Deferred income taxes | — | — | — | — | — | — | $0 | — |
| Change in accounts payable | $1.8M | $1.1M | $2.2M | -$31.0K | $1.2M | -$2.1M | $2.3M | -$2.1M |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$103.2M | -$98.1M | -$99.2M | -$119.5M | -$91.7M |
| Net income | -$97.2M | -$100.5M | -$93.6M | -$120.4M | -$92.9M |
| EPS (diluted) | $-0.62 | $-1.00 | $-2.11 | $-3.78 | $-3.93 |
| EPS (basic) | $-0.62 | $-1.00 | $-2.11 | $-3.78 | $-3.93 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $24.1M | $40.9M | $54.3M | $127.8M | $139.1M |
| Total liabilities | $30.7M | $22.4M | $25.4M | $14.1M | $12.0M |
| Stockholders' equity | -$6.7M | $18.4M | $28.9M | $113.7M | $127.1M |
| Total current assets | $22.9M | $39.3M | $52.5M | $125.9M | $105.0M |
| Total current liabilities | $30.6M | $22.2M | $24.7M | $13.1M | $11.4M |
| Cash & equivalents | $15.5M | $35.7M | $46.7M | $106.7M | $86.9M |
| Other current assets | $1.2M | $1.1M | $1.1M | $1.2M | $1.1M |
| Property, plant & equipment | $608.0K | $545.0K | $466.0K | $294.0K | $152.0K |
| Goodwill | — | — | — | $0 | $33.0M |
| Other non-current assets | — | — | $0 | $43.0K | $42.0K |
| Accounts payable | $10.1M | $7.8M | $5.1M | $4.3M | $3.7M |
| Accrued liabilities | $18.6M | $12.9M | $18.7M | $8.0M | $7.1M |
| Other current liabilities | $1.8M | $1.4M | $966.0K | $810.0K | $585.0K |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $9.0K | $8.0K | $4.0K | $4.0K | $3.0K |
| Retained earnings | -$608.6M | -$511.4M | -$410.9M | -$317.3M | -$196.9M |
| Accumulated other comprehensive income (loss) | $2.6M | $4.2M | $3.8M | $3.0M | -$252.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$85.8M | -$84.8M | -$70.8M | -$65.1M | -$83.2M |
| Investing cash flow | -$161.0K | -$264.0K | $9.5M | -$9.7M | -$67.0K |
| Financing cash flow | $65.6M | $74.5M | $1.0M | $95.8M | $42.8M |
| Free cash flow | -$86.0M | -$85.0M | -$71.2M | -$65.3M | -$83.3M |
| Capital expenditures | $161.0K | $264.0K | $334.0K | $112.0K | $67.0K |
| Depreciation & amortization | $168.0K | $134.0K | $111.0K | $77.0K | $85.0K |
| Share-based compensation | $8.9M | $8.5M | $7.1M | $7.9M | $5.9M |
| Deferred income taxes | — | $0 | $0 | $0 | $0 |
| Change in accounts payable | $1.2M | $3.1M | $817.0K | $799.0K | $176.0K |
| Debt repaid | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding IMUX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:54 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-11 | 8-K | 2026-09-10 | View on SEC.gov → |
| 2026-09-09 | 8-K | 2026-09-09 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-07-14 | 8-K | 2026-07-14 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-05 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-05 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-05 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-05 | View on SEC.gov → |
Recent news
Headlines about IMUX (Immunic, Inc.). Links open the publisher — we don’t host full articles.
-
Immunic, Inc. (IMUX) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
Immunic presents data on vidofludimus calcium at MS conference By Investing.com
Investing.com Australia · 2026-10-21 -
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Yahoo · 2026-10-21 -
Immunic, Inc. (IMUX) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Twelve analysts set a USD 35.43 target for Immunic stock
AD HOC NEWS · 2026-10-20 -
Immunic to showcase phase 2 long-term MS disability data at MSToronto2026
Yahoo · 2026-10-19 -
Immunic Appoints Jaa Roberson as Chief People Officer Ahead of Phase 3 Results
citybiz · 2026-10-19 -
IMUX Jan 2027 17.500 call (IMUX270115C00017500) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-19
No headlines in this category right now — try “All”.